ORGANIGRAM GLOBAL INC.
Organigram is a Canadian licensed producer of cannabis and cannabis-derived products for consumers in Canada. Its operations include cultivation and processing, with facilities in Moncton, Winnipeg, Lac-Supérieur, Aylmer and London. Products include dried flower, pre-rolls, infused pre-rolls, edibles, vapes, extracts and hash. Its adult-use brands include SHRED, BOXHOT, Big Bag O’ Buds, Edison, Monjour and Tremblant. Organigram also offers medical cannabis to patients in Canada and international customers. The company sells adult-use products through provincial and territorial distribution arrangements and medical cannabis through MyMedi.ca, an online platform managed by Avicanna Inc. It also exports products and works with local manufacturing partners in international markets. Its business-to-business services include tolling, extraction and white-label production. Organigram is headquartered in Toronto.
No SEC Form 4 filings for $OGI in the last 30 days.
See all $OGI insider activity →Organigram to acquire Aurora for C$7.80 per share, a 93% premium over Aurora's unaffected price. The deal, supported by both boards, values Aurora at approximately C$1.33B. Aurora shareholders can choose cash, shares, or a mix. The combined company aims to enhance scale, supply chain, and global footprint. Organigram's significant shareholder, BAT, will participate in financing.
CIRO halted trading for Organigram Global Inc. (OGI) on the TSX at 8:26 AM ET due to pending news. The halt aims to ensure a fair and orderly market. CIRO oversees investment dealers and trading activity in Canada.
Organigram Global Inc. (OGI) announced a restructuring plan to integrate its Sanity Group GmbH acquisition and achieve annualized cost savings of $8M-$10M by fiscal 2027. The plan includes discontinuing three brands, reducing product assortment, and reorganizing global operations. One-time costs of $2M are expected in fiscal 2027. CEO James Yamanaka stated the changes aim to improve profitability in Canada.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning OGI (ORGANIGRAM GLOBAL INC.). Coverage has skewed bullish: 2 bullish, 4 neutral, and 0 bearish.
Recent OGI coverage spans earnings, market movers and corporate actions.
Organigram’s offer and financing plan are likely credit-positive for deal certainty, but dilution and integration execution drive the stock’s risk-reward.
The halt itself is the actionable catalyst, with uncertainty until the pending news is released and trading resumes.
Cost‑cutting should improve margins and may lift the stock.
Cost reductions and portfolio simplification should improve gross margins and may support modest share price upside.
The earnout amendment provides certainty on future cash and share payments, likely supporting the stock price by reducing execution risk.
AlphAI scores every news story that mentions OGI with an AI model for sentiment and relevance, and aggregates insider trades from ORGANIGRAM GLOBAL INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Organigram to acquire Aurora for C$7.80 per share, a 93% premium over Aurora's unaffected price. The deal, supported by both boards, values Aurora at approximately C$1.33B. Aurora shareholders can choose cash, shares, or a mix. The combined company aims to enhance scale, supply chain, and global footprint. Organigram's significant shareholder, BAT, will participate in financing.
6 min readCIRO halted trading for Organigram Global Inc. (OGI) on the TSX at 8:26 AM ET due to pending news. The halt aims to ensure a fair and orderly market. CIRO oversees investment dealers and trading activity in Canada.
1 min readOrganigram Global Inc. (OGI) announced a restructuring plan to integrate its Sanity Group GmbH acquisition and achieve annualized cost savings of $8M-$10M by fiscal 2027. The plan includes discontinuing three brands, reducing product assortment, and reorganizing global operations. One-time costs of $2M are expected in fiscal 2027. CEO James Yamanaka stated the changes aim to improve profitability in Canada.
2 min readOrganigram plans to discontinue three cannabis brands and streamline operations, expecting annual savings of $8M by fiscal 2028. The company aims to reduce costs and improve margins by consolidating global functions and focusing on core brands. One-time costs of $2M are expected in fiscal 2027. According to management, these changes are part of a strategy to enhance profitability and operational efficiency.
2 min readOrganigram Global Inc. (OGI) accelerated the integration of Sanity Group, aligning leadership and operations. Sanity contributed CAD 40 million (35% of revenue) in the last quarter, with revenue growing 34% to €25.5 million. The company amended the earnout agreement, fixing it at 85% of the maximum value, with €20 million in cash and €76 million in shares payable in 2027. New leadership roles were appointed to support global growth.
2 min readOrganigram (OGI) reported Q3 2026 revenue of $105.8M, up 49% YoY, driven by Sanity Group acquisition. Adjusted EBITDA rose 136% to $13.4M. International sales now 35% of total revenue. CEO Yamanaka highlighted strategic transformation and record THC potency. CFO Guyatt expects margins to exceed fiscal 2025 levels. The company faces EU supply constraints and U.S. regulatory uncertainty.
6 min readOrganigram Global Inc. reported Q3 2026 record net revenue and adjusted EBITDA, citing Sanity Group’s first consolidation and Canada operational efficiencies. International revenue rose to about 35% of total. It reiterated FY2026 revenue guidance above $350 million and expects Q4 positive free cash flow. Net income was $105.5 million, including $105.8 million fair value gains.
7 min readSimply Wall St reports Organigram Global (TSX:OGI) shares were up about 23% before its Q3 release, trading near CA$1.69 with a trailing P/E of 2.7x. Q3 revenue rose to CA$105.8m from CA$70.8m and net income to CA$105.5m from a CA$6.3m loss. Management guided FY2026 revenue above CA$350m, while free cash flow stayed negative.
6 min readOrganigram Global Inc. (OGI) reported Q3 fiscal 2026 results for the quarter ended June 30, 2026. The company said gross revenue rose to $145.1 million (+32% YoY), net revenue to $105.8 million (+49%), and adjusted EBITDA to $13.4 million (+136%). It cited Sanity Group’s acquisition contribution and noted a TSX share-price gain in early trading.
6 min readOrganigram Global Inc. (OGI) shares rose about 10.95% on Aug. 11, 2026, as investors focused on the company’s Sanity Group acquisition and expectations for cannabis market growth. The article cites quarterly revenue of about $59.8M, gross margin near 31.9%, and free cash flow around -$7.0M, with first consolidated results expected in August 2026.
4 min read
